JP7627661B2 - アザベンゾイミダゾール化合物及び医薬 - Google Patents

アザベンゾイミダゾール化合物及び医薬 Download PDF

Info

Publication number
JP7627661B2
JP7627661B2 JP2021556143A JP2021556143A JP7627661B2 JP 7627661 B2 JP7627661 B2 JP 7627661B2 JP 2021556143 A JP2021556143 A JP 2021556143A JP 2021556143 A JP2021556143 A JP 2021556143A JP 7627661 B2 JP7627661 B2 JP 7627661B2
Authority
JP
Japan
Prior art keywords
pyridin
methyl
trifluoromethyl
imidazo
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021556143A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2021095801A1 (https=
Inventor
幸也 及川
卓人 山中
祥 平井
和彦 脇田
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nippon Shinyaku Co Ltd
Original Assignee
Nippon Shinyaku Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nippon Shinyaku Co Ltd filed Critical Nippon Shinyaku Co Ltd
Publication of JPWO2021095801A1 publication Critical patent/JPWO2021095801A1/ja
Application granted granted Critical
Publication of JP7627661B2 publication Critical patent/JP7627661B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2021556143A 2019-11-13 2020-11-12 アザベンゾイミダゾール化合物及び医薬 Active JP7627661B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2019205344 2019-11-13
JP2019205344 2019-11-13
PCT/JP2020/042247 WO2021095801A1 (ja) 2019-11-13 2020-11-12 アザベンゾイミダゾール化合物及び医薬

Publications (2)

Publication Number Publication Date
JPWO2021095801A1 JPWO2021095801A1 (https=) 2021-05-20
JP7627661B2 true JP7627661B2 (ja) 2025-02-06

Family

ID=75912665

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021556143A Active JP7627661B2 (ja) 2019-11-13 2020-11-12 アザベンゾイミダゾール化合物及び医薬

Country Status (11)

Country Link
US (1) US12528813B2 (https=)
EP (1) EP4059933A4 (https=)
JP (1) JP7627661B2 (https=)
KR (1) KR102951288B1 (https=)
CN (1) CN114929697A (https=)
AU (1) AU2020384041A1 (https=)
BR (1) BR112022008571A2 (https=)
CA (1) CA3161582A1 (https=)
MX (1) MX2022005649A (https=)
TW (1) TW202128689A (https=)
WO (1) WO2021095801A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2992256T3 (es) 2018-05-08 2024-12-11 Nippon Shinyaku Co Ltd Compuestos de azabencimidazol y producto farmacéutico
BR112022008571A2 (pt) * 2019-11-13 2022-08-09 Nippon Shinyaku Co Ltd Composto de azabenzimidazol e medicamento
US20250092008A1 (en) 2021-08-10 2025-03-20 Ono Pharmaceutical Co., Ltd. Process for making an ep4 antagonist

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009510152A (ja) 2005-10-06 2009-03-12 ラボラトリオス・アルミラル・ソシエダッド・アノニマ Ａ２ｂアデノシン受容体アンタゴニストとしての、イミダゾピリジン誘導体
JP2013237634A (ja) 2012-05-14 2013-11-28 Dainippon Sumitomo Pharma Co Ltd 縮環イミダゾロン誘導体
WO2018157857A1 (zh) 2017-03-03 2018-09-07 江苏豪森药业集团有限公司 凋亡信号调节激酶抑制剂及其制备方法和应用

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5571819A (en) 1994-11-22 1996-11-05 Sabb; Annmarie L. Imidazopyridines as muscarinic agents
NO2005012I1 (no) 1994-12-28 2005-06-06 Debio Rech Pharma Sa Triptorelin og farmasoytisk akseptable salter derav
US6541669B1 (en) 1998-06-08 2003-04-01 Theravance, Inc. β2-adrenergic receptor agonists
UA73543C2 (uk) 1999-12-07 2005-08-15 Тераванс, Інк. Похідні сечовини, фармацевтична композиція та застосування похідного при приготуванні лікарського засобу для лікування захворювання, яке опосередковується мускариновим рецептором
JP2007523957A (ja) 2004-02-25 2007-08-23 スミスクライン・ビーチャム・コーポレイション 新規化学化合物
TW200538095A (en) 2004-03-11 2005-12-01 Theravance Inc Biphenyl compounds useful as muscarinic receptor antagonists
EP1723142A1 (en) 2004-03-11 2006-11-22 Theravance, Inc. Diphenylmethyl compounds useful as muscarinic receptor antagonists
EP1734820A4 (en) 2004-04-16 2008-01-23 Neurogen Corp Imidazopyrrazine, imidazopyridine, and imidazo-pyrimidine as CRF1 receptor ligands
EP1928437A2 (en) 2005-08-26 2008-06-11 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
PT2054405E (pt) 2006-07-11 2013-12-24 Dae Woong Pharma Novos derivados de biaril benzoimidazol e composição farmacêutica que compreende os mesmos
US8008307B2 (en) 2006-08-08 2011-08-30 Millennium Pharmaceuticals, Inc. Heteroaryl compounds useful as inhibitors of E1 activating enzymes
GB0706168D0 (en) 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds
MX2010007587A (es) 2008-01-24 2010-08-04 Ucb Pharma Sa Compuestos que comprenden un grupo ciclobutoxi.
EP2810951B1 (en) 2008-06-04 2017-03-15 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8110578B2 (en) 2008-10-27 2012-02-07 Signal Pharmaceuticals, Llc Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
WO2010130392A1 (de) 2009-05-11 2010-11-18 Ratiopharm Gmbh Desfesoterodin in form eines weinsäuresalzes
WO2011018894A1 (en) 2009-08-10 2011-02-17 Raqualia Pharma Inc. Pyrrolopyrimidine derivatives as potassium channel modulators
JP5667934B2 (ja) 2010-06-28 2015-02-12 大日本住友製薬株式会社 新規２環性複素環化合物からなる医薬
TWI541243B (zh) 2010-09-10 2016-07-11 拜耳知識產權公司 經取代咪唑并嗒
JP2013545779A (ja) 2010-12-17 2013-12-26 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 過剰増殖性障害の治療におけるｍｐｓ−１およびｔｋｋ阻害剤として使用するための６置換イミダゾピラジン
CA2821834A1 (en) 2010-12-17 2012-06-21 Bayer Intellectual Property Gmbh 6 substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
JP6038150B2 (ja) 2011-08-24 2016-12-07 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Ｎｅｄｄ８活性化酵素阻害剤
CA2893622A1 (en) 2012-12-05 2014-06-12 Chiesi Farmaceutici S.P.A. Novel compounds
CN105121439A (zh) 2013-02-19 2015-12-02 辉瑞公司 作为pde4亚型抑制剂用于治疗cns和其他病症的氮杂苯并咪唑化合物
GB201302927D0 (en) 2013-02-20 2013-04-03 Cancer Therapeutics Crc Pty Ltd Compounds
TWI647227B (zh) 2013-02-28 2019-01-11 日商安斯泰來製藥股份有限公司 ２－醯胺噻唑衍生物或其鹽
US9326976B2 (en) 2014-06-05 2016-05-03 Chiesi Farmaceutici S.P.A. Carbamate derivatives
EA031866B1 (ru) 2014-06-06 2019-03-29 Астеллас Фарма Инк. Производное 2-ациламинотиазола или его соль
BR112017003901A2 (pt) 2014-08-26 2017-12-12 Astellas Pharma Inc derivado de 2-aminotiazola ou sal do mesmo
ES2907622T3 (es) 2014-10-06 2022-04-25 Merck Patent Gmbh Compuestos de heteroarilo como inhibidores de BTK y usos de estos
JP6680297B2 (ja) 2015-04-28 2020-04-15 アステラス製薬株式会社 経口投与用医薬組成物
WO2018112840A1 (en) 2016-12-22 2018-06-28 Merck Sharp & Dohme Corp. 6, 5-fused heteroaryl piperidine ether allosteric modulators of the m4 muscarinic acetylcholine receptor
CA3085745A1 (en) 2017-12-21 2019-06-27 Kyorin Pharmaceutical Co., Ltd. An agent for treating nocturnal pollakiuria
WO2019189766A1 (ja) 2018-03-30 2019-10-03 持田製薬株式会社 新規ビアリールアミド誘導体
ES2992256T3 (es) 2018-05-08 2024-12-11 Nippon Shinyaku Co Ltd Compuestos de azabencimidazol y producto farmacéutico
TW202012415A (zh) 2018-05-08 2020-04-01 瑞典商阿斯特捷利康公司 化學化合物
TWI721623B (zh) 2018-10-31 2021-03-11 美商基利科學股份有限公司 經取代之6-氮雜苯并咪唑化合物
BR112022008571A2 (pt) * 2019-11-13 2022-08-09 Nippon Shinyaku Co Ltd Composto de azabenzimidazol e medicamento
WO2021095805A1 (ja) 2019-11-13 2021-05-20 日本新薬株式会社 機能性消化管障害及び口腔乾燥症の治療剤及び予防剤

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009510152A (ja) 2005-10-06 2009-03-12 ラボラトリオス・アルミラル・ソシエダッド・アノニマ Ａ２ｂアデノシン受容体アンタゴニストとしての、イミダゾピリジン誘導体
JP2013237634A (ja) 2012-05-14 2013-11-28 Dainippon Sumitomo Pharma Co Ltd 縮環イミダゾロン誘導体
WO2018157857A1 (zh) 2017-03-03 2018-09-07 江苏豪森药业集团有限公司 凋亡信号调节激酶抑制剂及其制备方法和应用

Also Published As

Publication number Publication date
EP4059933A1 (en) 2022-09-21
BR112022008571A2 (pt) 2022-08-09
EP4059933A4 (en) 2023-11-15
CN114929697A (zh) 2022-08-19
KR20220100627A (ko) 2022-07-15
CA3161582A1 (en) 2021-05-20
US12528813B2 (en) 2026-01-20
WO2021095801A1 (ja) 2021-05-20
TW202128689A (zh) 2021-08-01
JPWO2021095801A1 (https=) 2021-05-20
MX2022005649A (es) 2022-06-22
US20230002395A1 (en) 2023-01-05
KR102951288B1 (ko) 2026-04-13
AU2020384041A1 (en) 2022-06-09

Similar Documents

Publication Publication Date Title
KR101860583B1 (ko) 피라졸로퀴놀린 화합물
US12319683B2 (en) Azabenzimidazole compounds and pharmaceutical
JP7627661B2 (ja) アザベンゾイミダゾール化合物及び医薬
WO2021107023A1 (ja) シクロアルキルウレア誘導体
CA3211637A1 (en) Compounds having tetrahydroindolizine-1-carboxamide as bcl-2 inhibitors
HK40075503A (en) Azabenzimidazole compound and medicine
HK40076325A (en) Azabenzimidazole compound and medicine
KR102904268B1 (ko) Cgrp 길항제 화합물
RU2804485C2 (ru) Азабензимидазольные соединения и фармкомпозиция
HK40046611B (en) Azabenzimidazole compounds and pharmaceutical
HK40046611A (en) Azabenzimidazole compounds and pharmaceutical
HK40045733B (zh) 氮杂苯并咪唑化合物和医药
HK40045733A (en) Azabenzimidazole compounds and pharmaceutical
WO2025117886A1 (en) Ulk complex modulators and uses thereof
TW202334096A (zh) 喹唑啉衍生化合物及其用途

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231024

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240910

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241108

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241224

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250121

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250127

R150 Certificate of patent or registration of utility model

Ref document number: 7627661

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150